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Genetic variant in IL-32 is 
associated with the ex vivo cytokine 
production of anti-TNF treated 
PBMCs from rheumatoid arthritis 
patients
Michelle S. M. A. Damen1,5, Kiki Schraa1, Lieke Tweehuysen2, Alfons A. den Broeder2, 
Mihai G. Netea  1,3, Calin D. Popa2,4 & Leo A. B. Joosten  1
About 60% of RA patients don’t achieve good response with biological disease-modifying anti-
rheumatic drugs bDMARD treatment (including TNF inhibitors, TNFi’s). Previously, a link between TNFα 
and interleukin (IL)-32 was reported in RA. However, the exact mechanism linking IL-32 to response to 
treatment as not been studied yet. Therefore, we explored the influence of a promoter single nucleotide 
polymorphism (SNP) rs4786370 in IL-32 on clinical responsiveness to TNFi’s in RA patients, potentially 
serving as new biomarker in RA. Expression of pro-inflammatory cytokines by peripheral mononuclear 
cells (PBMCs) from RA patients and healthy individuals were studied. Moreover, “ex vivo response” and 
clinical response to anti-TNFα therapy (etanercept, adalimumab) were measured and stratified for the 
IL-32 SNP. Higher IL-32 protein production was observed in RA patients. Additionally, patients bearing 
the CC genotype showed higher IL-32 protein and cytokine expression. DAS28 was independent of the 
promoter SNP, however, the “ex vivo” cytokine response was not. IL-32 mRNA and protein production 
was higher in RA patients, with a trend towards higher concentrations in patients bearing the CC 
genotype. Furthermore, genotype dependent IL-1 beta production might predict clinical response to 
etanercept/adalimumab. This indicates that IL-32 could play a role in predicting response to treatment 
in RA.
Rheumatoid arthritis (RA) is a common autoimmune and chronic inflammatory disease affecting about 1% of 
the population1,2. RA is characterized by persistent joint inflammation, progressive disability and ongoing sys-
temic inflammation, which can lead to joint deformity and low quality of life. Moreover, these characteristics 
are also able to increase the risk for atherosclerosis and cardiovascular disease (CVD), which is the main cause 
of death in these patients3–5. The clinical course of RA varies tremendously between patients from spontaneous 
remission, to mild joint symptoms to severe bone destruction. Early and aggressive treatment has been shown 
to improve the outcome. The introduction of biological disease-modifying anti-rheumatic drugs (bDMARDs) 
in combination with a “treat-to-target” treatment strategy significantly improved the disease outcomes in RA. 
These bDMARDs however still only achieve good response in about 40% of RA patients. The variation in clinical 
response to bDMARDs could be explained by variations in drug concentration and pharmacokinetics, which in 
turn are influenced by age, gender and renal or liver function6. Alternatively, the genetic background may also 
play a role and the interplay with the other factors could conduct towards specific profiles and increase the chance 
of achieving a good clinical response, suggesting a niche personalized medicine.
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The pathogenesis of RA still remains partly unknown but results in a chronic inflammatory state. The initial 
phase involves the activation of T and B cells and the induction of pro-inflammatory cytokines such as IL-6, 
IL-1β and TNFα7–9. TNFα is clearly of high importance in the pathogenesis of RA, which is shown by the fact 
that TNFi’s can effectively reduce the chronic inflammation in RA10,11. Moreover, TNFα is also capable of induc-
ing other pro-inflammatory mediators, such as chemokines and cytokines IL-6, IL-1β and IL-32, all found to be 
important in RA11,12. Studies of the last decade have shown that the cytokine interleukin-32 (IL-32) by itself is 
a strong inducer of TNFα and the expression levels of IL-32 in synovial biopsies correlated with inflammation 
severity in RA13,14. Moreover, overexpression of IL-32γ in human synovial fibroblasts followed by stimulation of 
TLR2/NOD2, showed a potent induction of TNFα mRNA15. In contrast, when IL-32 was- suppressed, TNFα 
production was decreased in human monocytes, all showing the important pro-inflammatory properties of 
IL-32 and its close relation with TNFα15,16. Despite knowing the interaction between these two cytokines and the 
importance in RA, research on the specific role of IL-32 in RA remains scarce. Our group recently showed a role 
for a promoter single-nucleotide polymorphism (SNP) in IL-32 that seemed to be associated with cytokine pro-
duction, IL-32 isoform expression and high-density cholesterol (HDLc) levels in RA patients17. The present study 
therefore aims to investigate the possible predictive implications of this SNP in the IL-32 gene on the severity of 
the disease and the clinical response to TNFI’s (including adalimumab or etanercept) in RA patients.
Results
IL-32 isoform mRNA expression in RA patients versus healthy subjects. PBMCs of RA patients 
(n = 22) and those of healthy individuals (n = 7) were isolated and IL-32β and IL-32γ mRNA expression were 
determined. First, IL-32β and IL-32γ isoforms expression was determined in unstimulated PBMCs, independent 
of the IL-32 promoter SNP genotype (Fig. 1A,B). Although no significant differences were observed, there is a 
clear trend towards more IL-32β and IL-32γ mRNA expression in the RA patients compared to the healthy indi-
viduals (Fig. 1A,B). Thereafter we examined whether the IL-32 promoter SNP genotype (T/C) would influence 
this latter result (Fig. 1C,D). Unstimulated PBMCs of RA patients with the TT-genotype showed a tendency 
towards higher IL-32β mRNA expression compared to healthy individuals (Fig. 1C). RA patients bearing the 
CC-genotype did not show differences on IL-32β mRNA expression neither in unstimulated nor in the case 
PBMCs have been stimulated with recombinant human TNFα (rhTNFα) (Fig. 1C). Exploring specifically IL-32γ, 
a trend towards higher IL-32γ mRNA expression in unstimulated PBMCs of patients bearing the CC genotype 
could be observed. When stimulated with rhTNFα, RA patients bearing the TT-genotype seemed to express 
more IL-32γ compared to the unstimulated condition and the expression of IL-32γ in the group bearing the 
CC-genotype. However, none of these observations were statistical significant (Fig. 1D).
Figure 1. mRNA expression of IL-32 isoforms IL-32β, IL-32γ, in RA patients and healthy individuals in 
(un)stimulated PBMCs also separated on IL-32 promoter SNP genotypes. (A) mRNA expression of IL-32β 
in PBMCs from healthy individuals versus RA patients in unstimulated PBMCs (n = 7 healthy individuals; 
n = 22 RA patients). (B) mRNA expression of IL-32γ in PBMCs from RA patients and healthy individuals 
in unstimulated PBMCs (n = 7 healthy individuals; n = 22 RA patients). (C) mRNA expression of IL-32β in 
unstimulated PBMCs or PBMCs stimulated with rhTNFα from RA patients versus healthy individuals with the 
CC- versus TT-genotype for the IL-32 promoter SNP (n = 13 TT; n = 9 CC RA patients). (D) mRNA expression 
of IL-32γ in unstimulated PBMCs or PBMCs stimulated with rhTNFα from RA patients versus healthy 
individuals with the CC- versus TT-genotype for the IL-32 promoter SNP (n = 13 TT; n = 9 CC RA patients).
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IL-32 protein expression is highest in RA patients bearing the CC-genotype. Even though there 
were no significant differences observed in IL-32β and IL-32γ isoforms mRNA expression between RA patients 
and healthy individuals, independent of IL-32 promoter SNP, the endogenous IL-32 protein expression was 
investigated. IL-32 protein concentration was determined in the two groups as a whole as well as stratified for 
IL-32 promoter SNP (Fig. 2A,B). Figure 2A shows a significantly higher IL-32 protein expression in RA patients 
compared to healthy individuals in unstimulated PBMCs. Of note, the production of IL-32 protein was signif-
icantly higher especially in the RA patients with the CC-genotype (Fig. 2B), whereas in the group bearing the 
TT-genotype it did not reach statistical significance.
A pro-inflammatory status of RA PBMCs bearing the CC-genotype. After observing differences 
in IL-32 mRNA isoforms expression and IL-32 protein expression between RA patients and healthy individuals, 
we examined the potential role of the CC-genotype in RA patients. We were interested to determine whether 
the genotypes in IL-32 promoter SNP would be associated with a different inflammatory response. In order to 
explore this, we investigated the capacity of ex-vivo cytokine production by PBMCs after exposure with vari-
ous pro-inflammatory stimuli. Figure 3A,B clearly showed that PBMCs isolated from RA patients bearing the 
CC-genotype produce more IL-6 and IL-8, compared to TT genotype. Depending on the stimuli, the enhanced 
production of IL-8 reached statistical significance after PBMCs have been stimulated with rhIL-1β (Fig. 3B). In 
line with these results, PBMCs bearing the CC genotype produce more IL-1Ra, although this was not statistical 
significant.
DAS28-CRP is not affected by IL-32 promoter SNP genotypes. After observing that RA patients, 
particularly those bearing the CC-genotype of the IL-32 SNP promoter, produce more pro-inflammatory 
cytokines, we thought to investigate whether this could have an impact on disease activity of these RA patients. 
To quantify disease activity, we used well-established DAS28-CRP score. DAS28-CRP scores were measured at 
baseline and after 3 and 6 months of follow-up. As shown in Fig. 4A, no differences were observed in DAS28-CRP 
scores between the two genotypes for the IL-32 promoter SNP at baseline. In the subgroups of patients who 
started treatment with respectively adalimumab or etanercept. IL-32 genotype did not influence the DAS28-CRP 
at three as well as six months afterwards (Fig. 4B,C).
IL-32 genotype could help to predict the response on etanercept and adalimumab in RA. In 
order to provide a possible explanation for the fact that the IL-32 promoter SNP did not influence the response 
of RA patients to therapy with adalimumab or etanercept in the first six months, we further thought to assess 
whether the genotype could affect the ex vivo response of PBMCs to various stimuli in the presence of etanercept 
or adalimumab. In addition, we also wanted to address the question whether patients who eventually show a good 
clinical response to these bDMARDs have a different inflammatory response at baseline dependent on the IL-32 
genotype. More specifically, if RA patients with either the CC or TT genotype would respond better to the specific 
bDMARD by showing a different cytokine response (Fig. 5A–D and Supplementary Fig. S1 and Tables T1, T2). 
IL-1β production by PBMCs tends to decrease after Candida albicans stimulation in the presence of either adali-
mumab or etanercept (Fig. 5A). When the IL-1β cytokine production was stratified for clinical responders versus 
non-responders to either etanercept or adalimumab (Figs 5B and Supplementary S1), higher IL-1β production in 
the clinical responders was noted, though not reaching statistical significance. We further divided these groups 
according to their genotype for the IL-32 promoter SNP. Figure 5C,D and Supplementary Fig. S1 indicate that 
for the clinical responders to either etanercept or adalimumab, RA patients bearing the CC genotype seem to 
produce more IL-1β after ex vivo stimulation of PBMCs, even reaching a statistical significant difference in the 
case of etanercept treatment. In contrast, no such effect was observed for RA patients bearing the TT genotype. 
To try and explain this effect in more detail we calculated the percentage of ex vivo responders to etanercept and 
Figure 2. Protein expression of total IL-32 in unstimulated PBMCs from healthy individuals and RA patients 
also stratified for IL32 promoter SNP. (A) A statistical significant difference was found in IL-32 protein 
expression between these groups (p = 0,0044) using the Mann-Whitney test in Graphpad Prism v5.03 (n = 8 
TT healthy individuals and n = 25 TT RA patients versus n = 8 CC healthy individuals and n = 14 CC RA 
patients). (B) IL-32 protein concentrations were stratified for the IL-32 promoter SNP genotypes TT and CC. 
A significantly higher concentration of IL-32 protein was found in the RA patients carrying the CC-genotype 
compared to healthy individuals with the same genotype (p = 0.0105).
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adalimumab. This data however does not show to be able to predict a possible effect of the IL-32 promoter SNP on 
the clinical responsiveness of RA patients to anti-TNFα therapy (Supplementary Tables T1, T2).
Discussion
In this study, we showed that mRNA expression levels of IL-32 isoforms IL-32β and IL-32γ tended to be higher 
in PBMCs isolated from RA patients as compared to healthy individuals. Additionally, intracellular IL-32 protein 
production was higher in RA patients, especially in those bearing the CC-genotype. These patients also tended 
to produce more pro-inflammatory cytokines in-vitro. However, this fact did not translate into a higher disease 
activity, as assessed by DAS28-CRP scores. Finally, ex-vivo PBMCs stimulations in the presence of the intended 
medication could potentially identify the patients who would become responders according to clinical criteria. 
The determination of IL-32 promoter SNP in this context proved to have crucial importance.
IL-32 mRNA isoforms have been studied so far in many different cell types and diseases including chronic 
obstructive pulmonary disease (COPD), various types of cancer and RA14,18–20. Nevertheless, the exact expression 
pattern of the isoforms in specific cells or tissues and the function of each isoform still need to be elucidated20. 
It is known that the structure of the two isoforms IL-32β and IL-32γ is quite similar21. Both isoforms seem to 
be involved in pro-inflammatory processes, including the induction of other pro-inflammatory cytokines and 
chemokines like IL-8, IL-6, IL-1β and TNFα. In our study, we found a higher IL-32 protein production from 
Figure 3. Cytokine measurements in PBMCs from RA patients and stratified for the IL-32 promoter SNP 
after stimulation with either Poly I:C and rhIL-1β or rhTNFα. (A) IL-6 protein concentration in PBMCs of RA 
patients with the TT- versus CC-genotype for the promoter SNP, at basal level and after stimulation. (B) IL-8 
protein concentration in PBMCs of RA patients with the TT- versus the CC-genotype for the IL-32 promoter 
SNP, at basal level and after stimulation. Significant differences were observed after rhIL-1β stimulation between 
the CC- versus TT-genotype (p = 0.0335). (C) IL-1Ra protein concentration in PBMCs of RA patients with 
the TT- versus CC-genotype for the IL-32 promoter SNP at basal level as well as after stimulation. Statistical 
significance was shown by * when p < 0.05, GraphpadPrism V5.03. (n = 27 TT RA patients and n = 15 CC RA 
patients).
Figure 4. Disease activity scores (DAS) 28 in RA patients stratified on IL-32 promoter SNP and therapy used 
(etanercept or adalimumab). (A) DAS 28CRP separated on IL-32 promoter SNP genotype and independent 
of therapy (n = 37 CC vs 85 TT). (B) DAS28CRP separated on IL-32 promoter SNP genotype and Etanercept 
therapy (n = 13 CC vs 32 TT). (C) DAS28CRP separated on IL-32 promoter SNP genotype and Adalimumab 
therapy (n = 4 CC vs 13 TT).
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PBMCs of RA patients together with a slightly higher IL-32 mRNA expression in the same patients. This is in 
line with previous data pointing to a higher IL-32 mRNA expression in fibroblast-like synoviocytes (FLS) of RA 
patients and also in the PBMCs21,22. Interestingly, here we show that only in patients bearing the CC-genotype, the 
increase in plasma IL-32 concentrations reaches statistical significance. This could also be due to the low number 
of patients included for this analysis. Alternatively, this might suggest that the studied SNP in IL-32 promoter has 
functional consequences. Finally, a difference between isoforms expression has been observed within the patients, 
which varied from the expression pattern seen in healthy individuals.
In a previous study, we indicated that the promoter SNP is associated with different levels of high-density lipo-
protein cholesterol (HDLc) concentrations in RA patients, namely higher HDLc concentrations17. These results 
already suggested that this SNP might be functional. In the present report, we extended our observations at the 
level of cytokine production and immune responses. PBMCs from RA patients showed a difference in cytokine 
production when the patients were separated according to their genotype. Our study is the first to show that and 
therefore confirms the fact that the promoter SNP serves a functional effect.
Given the contribution of IL-32 and TNF to the inflammatory cascade in RA, we further investigated whether 
the SNP in IL-32 promoter region impacts disease activity in these patients. Absolute levels of disease activity 
are set to define the disease state of the patients and over time can be used to define improvement or response 
to treatment23. Finding a marker that could predict the latter would therefore be useful, although current treat 
to target treatment strategies already have very good long term outcomes. Unfortunately, this study showed that 
the promoter SNP in IL-32 was not such a marker. Even though it has functional effects on cytokine production 
by PBMCs or on the HDLc concentration, no effect was seen on the level of disease activity, as measured by 
DAS28-CRP. These results are somehow in contrast with the study of Gui et al., which observed correlations 
between the IL-32 levels and disease activity22. The number of patients enrolled and the different design might 
explain this discrepancy. Alternatively, IL-32 might differently impact the various components of DAS28 score, 
for instance the number of tender joints or the VAS.
Single nucleotide polymorphisms in other cytokines such as TNFα, IL-1β and IL-6 have been studied in pos-
sible association to response to treatment in RA patients24–27. Since IL-32 is strongly linked to TNFα expression 
and can induce IL-6 and IL-1β, it was worth investigating whether this SNP also had an effect on clinical response 
Figure 5. Percentage of IL-1β production corrected for baseline IL-1β production induced by Candida IgG 
stimulation of PBMCs from RA patients in the presence of anti-TNFα treatment (etanercept). (A) IL-1β 
cytokine production after ex vivo stimulation of PBMCs from RA patients with additional etanercept or 
adalimumab for 24 h independent of clinical treatment (n = 121). (B) IL-1β cytokine production after ex vivo 
stimulation of PBMCs from RA patients with additional etanercept, stratified for RA patients that clinically 
responded or not to etanercept (n = 26 non-responders; n = 19 responders). (C) IL-1β cytokine production after 
ex vivo stimulation of PBMCs from RA patients with additional etanercept, stratified for clinical responders 
to etanercept treatment and IL-32 promoter SNP (n = 4 CC; n = 15 TT RA patients). Statistical significant 
differences were observed after Candida IgG (p = 0.0336) stimulation and Candida Etan (p = 0.0196). (D) IL-1β 
cytokine production after ex vivo stimulation of PBMCs from RA patients with additional etanercept, stratified 
for clinical non-responders to etanercept and IL-32 promoter SNP genotype (n = 9 CC and n = 17 TT RA 
patients). Statistical significance was shown by * when p < 0.05, GraphpadPrism V5.03.
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to treatment. No differences were observed when looking at the clinical response independent of treatment or 
anti-TNFα (etanercept or adalimumab) treatment in particular, when separated on the promoter SNP for IL-32.
Besides the clinical response, the ex vivo response of PBMCs stimulated with additional etanercept or adali-
mumab and Candida albicans or Pam3Cys was studied by looking at IL-1β cytokine production after stimulation. 
A previous study by Popa C et al. could not detect differences in IL-1β cytokine production after anti-TNFα 
treatment28. Interestingly, our data however showed that PBMCs of RA patients bearing the CC genotype pro-
duced more IL-1β after ex vivo stimulation only within the group of RA patients that clinically responded to 
either etanercept or possibly adalimumab treatment. No such differences were observed either for the clinical 
non-responders or patients bearing the TT genotype. This was in line with data from another study by Kayakabe 
K et al. which showed that IL-1β could serve as a possible predictive measurement for response to anti-TNFα 
treatments29.
These results suggest that even though the IL-32 promoter SNP does not have an effect on DAS28 scores, 
there might be a role for the genetic polymorphism in the promoter region of IL-32 in the prediction of clinical 
response to anti-TNFα treatment in RA patients also taking into account the observed influence on the pro-
duction of pro-inflammatory cytokines in these patients. Given the previously indicated relation between the 
promoter SNP and HDLc levels in RA patients and the new findings of the functional effect of the promoter SNP 
on cytokine production and response to treatment, these data show a possible additional role of IL-32 and its pro-
moter SNP in RA. Our results therefore lead to an area of research in which the effects of IL-32 and the promoter 
SNP in RA have to be studied relevant to response to treatment and cardiovascular diseases within these patients. 
In line with this, we are currently performing studies to further elucidate the mechanisms behind the role of IL-32 
in cholesterol metabolism regulation.
Some limitations could be envisaged in our study. One of the most important one might be related to the 
low number of patients per genotype (TT vs CC) for the IL-32 promoter SNP, especially in the analysis of the 
data concerning only patients who received etanercept or adalimumab. This is caused by the multiple strati-
fications e.g. genotypes, clinical responses; medications/treatments that were performed. This could interfere 
with statistical analysis and power in case a small difference in response to treatment would have been observed 
and sample size is small. In addition, healthy controls were not matched regarding age or gender to the patients 
group. Moreover, differences in cytokine production of TNFα were not measured directly and because of multiple 
freeze-thaw cycles, this was no longer possible. Therefore, this study lacks a very important cytokine measure-
ment within this group of patients.
In conclusion, the present study shows that IL-32 mRNA and protein production was higher in RA patients 
compared to healthy individuals. Moreover, this study is the first to show a slightly higher IL-32 expression in 
patients bearing the CC-genotype for the IL-32 promoter SNP (rs4786370). Additionally, the promoter SNP 
tended to be associated with an increased expression of pro-inflammatory cytokines IL-6 and IL-8 produced by 
PBMCs of RA patients. These findings add to the previously described functional effect of the IL-32 promoter 
SNP on HDLc concentrations within RA patients. Nevertheless, we were unable to show an association between 
the promoter SNP and disease activity and clinical response to adalimumab and etanercept. However, most inter-
estingly, we were able to show a link between the promoter SNP and the ex vivo induced cytokine production 
of IL-1β in RA patients that clinically responded to etanercept (or adalimumab). Therefore, we suggest that the 
exploration of the role of IL-32 in RA should be continued in future research, focussing more specifically on treat-
ment response, inflammation induced cardiovascular disease burden and cholesterol metabolism abnormalities.
Material and Methods
Patient cohort. Blood samples were obtained at baseline from patients included in the prospective longi-
tudinal prediction cohort study BIO-TOP [Biologic Individual Optimized Treatment Outcome Prediction] and 
isolated immune cells were used for various assays. RA patients >18 years, treated in the Sint Maartenskliniek 
(Nijmegen, the Netherlands) who were going to start with (or switch to) a biological disease-modifying anti-rheu-
matic drug (bDMARD) were included in this study. The local ethical committee (CMO region Arnhem-
Nijmegen, NL47946.091.14) was responsible for approval of the BIO-TOP study and a detailed description is 
available in the Dutch trial register (NTR4647 clinical trial, 17-jun-2014, NTR). Additionally, blood samples of 
healthy individuals were used and obtained on the same day of that of a patient. Written informed consent was 
received from all donors. Experiments with human blood were performed in accordance with the Declaration of 
Helsinki.
DNA isolation and taqman genotyping. Whole blood obtained from 329 RA patients in the BIOTOP 
study was used to perform genomic DNA extraction. Genomic DNA was isolated from whole blood using the 
Qiagen (Valencia, CA, USA) isolation kit and following the standard protocol. The samples were quantified and 
evaluated for purity (260/280-nm ratio) with a NanoDrop ND-1000 spectrophotometer (Thermo Scientific). 
Using the Taqman SNP assay C_27972515_20 (Thermofisher, Foster City, CA, USA), each genetic variant in the 
IL32 promoter (rs4786370) polymorphism was determined. The TaqMan qPCR assays were performed on the 
AB StepOnePlus polymerase chain reaction system (Applied Biosystems). Negative controls were included in the 
assay. No duplicates were used.
Isolation and ex-vivo stimulation of peripheral blood mononuclear cells (PBMCs). At baseline 
(before start bDMARD), venous blood was collected into three 10 mL EDTA tubes after informed consent. Within 
24 hours, PBMCs were isolated by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, Zeist, 
The Netherlands) and collecting the buffy-coat enriched layer. Cells were washed twice in cold PBS and concen-
trations were adjusted to 5 × 106 cells/ml in RPMI-1640, supplemented 2 mM l-glutamine, 1 mM pyruvate and 
50 μg/ml gentamicin (GIBCO Invitrogen, Carlsbad, CA). Mononuclear cells (5 × 105) in a 100-μl volume were 
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added to round-bottom 96-well plates (Greiner, Nurnberg, Germany) and incubated with either 100 μl of culture 
medium (negative control), Poly I:C (50uL Invivogen), IL-1β (1 ng/mL R&D Systems), or recombinant human 
TNFα (rhTNFα 10 ng R&D Systems). After 24 hour incubation at 37 °C, the supernatants were stored at −20 °C 
until further use. Besides these experiments, additionally 5 × 105 PBMCs were pre-incubated in round bottom 
96-well plates for one hour at 37 °C with therapeutic in vivo concentrations of adalimumab or etanercept. Taking 
into account the different half-life times, dosing and treatment intervals, and therapeutic concentration ranges of 
the anti-TNFα, the same concentration of 5 µg/mL was added for both anti-TNFα bDMARDS (4–6). Human IgG 
was used as negative control. Thereafter, cells were stimulated with either Pam3Cys (a TLR2 agonist) or heat killed 
Candida albicans (ATCC MYA-3573 (UC 820)). After 24 hours, supernatants were stored at −20 °C until assayed.
Cytokine measurements. Various cytokines were determined in supernatant after stimulation of PBMCs 
with recombinant human TNFα (10 ng/ml) (R&D Systems), recombinant human IL-1β (1 ng/mL R&D Systems) 
or Poly I:C (TLR3 agonist) (50 µg/ml) (Invivogen) for 24 hours, by commercially available ELISA kits according 
to manufacturer’s instructions. Concentrations of human IL-1β, IL-1Ra (R&D Systems, Inc., Minneapolis, MN, 
USA) and IL-6, IL-8, IL-10 (Sanquin Reagents, Amsterdam, The Netherlands) were measured. IL-32 production 
was measured in cell lysates (Triton X 100 0.5%) of PBMCs stimulated with various ligands, using the commer-
cially available ELISA kit (R&D Systems, Inc, Minneapolis, MN, USA). In brief, Maxisorp plates (Nunc) were 
coated with AF3040 (R&D Systems) diluted in Phosphate Buffered Saline (PBS) at a concentration of 0.4 μg/ml 
and incubated overnight at room temperature. Plates were blocked with PBS containing 1% BSA (Sigma-Aldrich) 
for 1 hour at room temperature. The standard curve was prepared by diluting recombinant IL-32 ranging from 
5000 pg/ml until 39.06 pg/ml in PBS containing 5% BSA. After a 2 hour incubation with the cell lysates, detection 
antibody was added (BAF3040, R&D Systems), 0.1 µg/ml in PBS with 5% BSA for 1 hour. Streptavidin (R&D 
Systems) was added for 30 minutes at room temperature after which substrate buffer was used to develop a color 
reaction that was measured by a plate reader.
Clinical assessments. Disease activity was measured with the 28-joints disease activity score using 
C-reactive protein (DAS28-CRP) during outpatient clinical visits performed in usual care after 3 and 6 months 
(±1 month). Primary outcome was the DAS28-CRP based European League Against Rheumatism (EULAR) 
response criteria (good versus moderate/no response) at month 6.
Statistical analysis. Normality was tested using the D’Agostino normality test. Continuous variables are 
presented as mean and standard deviation (SD). The differences IL-32 mRNA expression, IL-32 protein concen-
trations and cytokine concentrations were analyzed using the Mann-Whitney U-test. A p-value less than 0.05 was 
considered statistically significant (*p < 0.05 and **p < 0.01). Data was analyzed using GraphPad Prism v5.3.
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